Compare Crocs, Inc. (CROX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs GeneDx Holdings Corp — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.53B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Crocs, Inc. is far larger — about 2.7× GeneDx Holdings Corp's market cap, and Crocs, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and GeneDx Holdings Corp for 19 Days on average.
| CROX | WGS | |
|---|---|---|
Market Cap | $5.53B | $2.04B |
Volume | 967,176 | 659,215 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $167.51 |
52-Week Low | $73.39 | $34.51 |
Typical Hold Time | 96 Days | 19 Days |
Enterprise Value | $7.04B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $116.84, down 2.81% today, amid bearish technical signals but strong fundamental valuation metrics. The stock shows attractive P/E of 10.23 and P/S of 1.46, with robust profitability margins including 57.47% gross margin and 42.3% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.55 surpassing the $4.35 estimate. The company maintains strong cash flow generation despite a net loss in 2025, with management focusing on product innovation and HEYDUDE brand repositioning.
CROX presents a compelling value opportunity with discounted valuation multiples relative to historical performance, though near-term technical weakness and competitive pressures warrant caution. Analyst consensus remains bullish with $136.78 price target representing 17% upside potential. Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification initiatives. The stock's current levels offer entry points for long-term investors seeking exposure to a profitable footwear company with strong brand recognition.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
